» Articles » PMID: 30545129

Inhibitors of the VEGF Receptor Suppress HeLa S3 Cell Proliferation Via Misalignment of Chromosomes and Rotation of the Mitotic Spindle, Causing a Delay in M-Phase Progression

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2018 Dec 15
PMID 30545129
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Cell division is the process by which replicated chromosomes are separated into two daughter cells. Although regulation of M phase has been extensively investigated, not all regulating factors have been identified. Over the course of our research, small molecules were screened to identify those that regulate M phase. In the present study, the vascular endothelial growth factor receptor (VEGFR) inhibitors A83-01, SU4312, and Ki8751 were examined to determine their effects on M phase. Treatment of HeLa S3 cells with these inhibitors suppressed cell proliferation in a concentration-dependent manner, and also suppressed Akt phosphorylation at Ser473, a marker of Akt activation. Interestingly, cleaved caspase-3 was detected in Adriamycin-treated cells but not in inhibitor-treated cells, suggesting that these inhibitors do not suppress cell proliferation by causing apoptosis. A cell cycle synchronization experiment showed that these inhibitors delayed M phase progression, whereas immunofluorescence staining and time-lapse imaging revealed that the M phase delay was accompanied by misalignment of chromosomes and rotation of the mitotic spindle. Treatment with the Mps1 inhibitor AZ3146 prevented the SU4312-induced M phase delay. In conclusion, the VEGFR inhibitors investigated here suppress cell proliferation by spindle assembly checkpoint-induced M phase delay, via misalignment of chromosomes and rotation of the mitotic spindle.

Citing Articles

DeSUMOylating isopeptidase 1 participates in the faithful chromosome segregation and vincristine sensitivity.

Ikeda Y, Yuki R, Saito Y, Nakayama Y FASEB J. 2024; 38(24):e70261.

PMID: 39698932 PMC: 11656513. DOI: 10.1096/fj.202401560RR.


Phosphorylation of Ephexin4 at Ser-41 contributes to chromosome alignment via RhoG activation in cell division.

Yasutake R, Kuwajima H, Yuki R, Tanaka J, Saito Y, Nakayama Y J Biol Chem. 2024; 301(1):108084.

PMID: 39675713 PMC: 11758948. DOI: 10.1016/j.jbc.2024.108084.


Extracellular vesicles, including large translating vesicles called midbody remnants, are released during the cell cycle.

Patel S, Park S, Zhu D, Torr E, Dureke A, McIntyre A Mol Biol Cell. 2024; 35(12):ar155.

PMID: 39535882 PMC: 11656471. DOI: 10.1091/mbc.E23-10-0384.


VEGFR2 blockade inhibits glioblastoma cell proliferation by enhancing mitochondrial biogenesis.

Guo M, Zhang J, Han J, Hu Y, Ni H, Yuan J J Transl Med. 2024; 22(1):419.

PMID: 38702818 PMC: 11067099. DOI: 10.1186/s12967-024-05155-1.


Retinoic Acid Receptor Is a Novel Therapeutic Target for Postoperative Cognitive Dysfunction.

Bao Y, Rong W, Zhu A, Chen Y, Chen H, Hong Y Pharmaceutics. 2023; 15(9).

PMID: 37765280 PMC: 10538227. DOI: 10.3390/pharmaceutics15092311.


References
1.
Nigg E . Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001; 2(1):21-32. DOI: 10.1038/35048096. View

2.
Tian X, Song S, Wu J, Meng L, Dong Z, Shou C . Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem Biophys Res Commun. 2001; 286(3):505-12. DOI: 10.1006/bbrc.2001.5409. View

3.
Wu W, Shu X, Hovsepyan H, Mosteller R, Broek D . VEGF receptor expression and signaling in human bladder tumors. Oncogene. 2003; 22(22):3361-70. DOI: 10.1038/sj.onc.1206285. View

4.
Ryden L, Linderholm B, Nielsen N, Emdin S, Jonsson P, Landberg G . Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat. 2004; 82(3):147-54. DOI: 10.1023/B:BREA.0000004357.92232.cb. View

5.
Kubo K, Shimizu T, Ohyama S, Murooka H, Iwai A, Nakamura K . Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. J Med Chem. 2005; 48(5):1359-66. DOI: 10.1021/jm030427r. View